Q1 FY27 results reported
As filed · Outcome of Board Meeting
EarningsMajormateriality 77 out of 100
What happened
FactAugust 10, 2026.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Guidance
WithdrawnEarlierFY27
Revenue: ~ 3x of FY24
NowFY27
Expect technology transfer revenues to start in Q4’FY27
Change
FactGuidance withdrawn
Implication
CapitSignal interpretationThe stated timeline moved by -12 quarter(s) (FY30 to Q4 FY27).confidence 60%
Earlier statement · FY27Latest statement · FY27
Guidance
DelayedEarlierFY27
Expect Technology transfer revenue to start in FY29
NowFY27
EBITDA Margin: More than 25%
Change
FactTimeline delay
Implication
CapitSignal interpretationThe stated timeline moved by 4 quarter(s) (FY29 to FY30).confidence 60%
Earlier statement · FY27Latest statement · FY27
Guidance
RevisedEarlierFY27
Revenue: Rs. 645 Cr.
NowFY27
Revenue: Rs. 558 Cr.
Change
FactTarget revision
Implication
CapitSignal interpretationThe revenue guidance for FY27 changed from Rs. 645 Cr. to Rs. 558 Cr., indicating a material revision.confidence 95%
Earlier statement · FY27Latest statement · FY27
Watch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- EBITDA Margin: More than 25% (management committed by FY30)
- Revenue: ~ 3x of FY24 (management committed by FY30)
Evidence
- Jubilant Pharmova Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.(opens the original filing in a new tab)
- Earlier statement · FY27
- Latest statement · FY27
- Earlier statement · FY27
- Latest statement · FY27
- Earlier statement · FY27
- Latest statement · FY27
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +4 corroborating keywords; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%